Stock Events

Stock Events

Coya Therapeutics 

$3.61
13
-$0.37-9.3%Friday 20:00
+$0.06+1.66%Friday 22:13After hours

Statistics

Day High
3.65
Day Low
3.6
52W High
6.62
52W Low
3.59
Volume
10,358
Avg. Volume
-
Mkt Cap
84.68M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 11Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.44
-0.34
-0.23
-0.13
Expected EPS
-0.34
Actual EPS
N/A

Financials

-267.13%Profit Margin
Unprofitable
2021
2022
2023
2024
2025
7.95MRevenue
-21.23MNet Income

Analyst Ratings

$14.00Average Price Target
The highest estimate is ⁦16.00⁩.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow COYA. It's not an investment recommendation.
NVIDIA
5
NVDA
Microsoft
4
MSFT
Amazon
4
AMZN
Tesla
4
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.49B
Biogen focuses on neurodegenerative diseases, directly competing with Coya Therapeutics' focus on neurodegenerative and autoimmune diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap29.4B
Alnylam Pharmaceuticals works on RNAi therapeutics for neurodegenerative diseases, competing in the same therapeutic area as Coya.
Ionis Pharmaceuticals
IONS
Mkt Cap7.24B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, including treatments for neurological diseases, making it a competitor.
PTC Therapeutics
PTCT
Mkt Cap5.3B
PTC Therapeutics focuses on the discovery and commercialization of novel medicines, including treatments for neurological disorders.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals is involved in developing treatments for a variety of diseases, including neurodegenerative diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.93B
Vertex Pharmaceuticals engages in creating new therapies for serious diseases, including a focus on genetic diseases that can overlap with Coya's work.
Novartis
NVS
Mkt Cap268B
Novartis is a large pharmaceutical company with a broad focus, including neurodegenerative diseases, making it a competitor in some of Coya's key areas.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie has a diverse portfolio that includes treatments for neurological conditions, directly competing with Coya Therapeutics.
AMGEN
AMGN
Mkt Cap217.9B
Amgen focuses on human therapeutics, including treatments for neurodegenerative diseases, making it a competitor in the same field as Coya.

About

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
Show More
CEO
Arun Swaminathan
Employees
8
Country
United States
ISIN
US22407B1089

Listings

XNAS
US
COYA
BOATS
BOATS
COYA.BOATS

0 Comments

Share your thoughts

FAQs

What is Coya Therapeutics stock price today?▼
The current price of COYA is $3.61 USD — it has decreased by -9.3% in the past 24 hours. Watch Coya Therapeutics stock price performance more closely on the chart.
What is Coya Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Coya Therapeutics stocks are traded under the ticker COYA.
Is Coya Therapeutics stock price growing?▼
COYA stock has fallen by -8.61% compared to the previous week, the month change is a -24.95% fall, over the last year Coya Therapeutics has showed a -42.88% decrease.
What is Coya Therapeutics market cap?▼
Today Coya Therapeutics has the market capitalization of 84.68M
When is the next Coya Therapeutics earnings date?▼
Coya Therapeutics is going to release the next earnings report on November 11, 2026.
What were Coya Therapeutics earnings last quarter?▼
COYA earnings for the last quarter are -0.28 USD per share, whereas the estimation was -0.35 USD resulting in a +19.01% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Coya Therapeutics revenue for the last year?▼
Coya Therapeutics revenue for the last year amounts to 7.95M USD.
What is Coya Therapeutics net income for the last year?▼
COYA net income for the last year is -21.23M USD.
How many employees does Coya Therapeutics have?▼
As of November 2, 2026, the company has 8 employees.
In which sector is Coya Therapeutics located?▼
Coya Therapeutics operates in the Health & Wellness sector.
When did Coya Therapeutics complete a stock split?▼
Coya Therapeutics has not had any recent stock splits.
Where is Coya Therapeutics headquartered?▼
Coya Therapeutics is headquartered in HOUSTON, United States.